Dissecting the Roles of PDCD4 in Breast Cancer

Qian Cai1,2, Hsin-Sheng Yang3, Yi-Chen Li4 and Jiang Zhu*,4

1 Department of Geriatric Medicine, Qilu Hospital of Shandong University, Jinan, China, 2 Key Laboratory of Cardiovascular Proteomics of Shandong Province, Qilu Hospital of Shandong University, Jinan, China, 3 Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, KY, United States, 4 Department of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, China

The human programmed cell death 4 (PDCD4) gene was mapped at chromosome 10q24 and encodes the PDCD4 protein comprised of 469 amino acids. PDCD4 inhibits protein translation to suppress tumor progression, and its expression is frequently decreased in breast cancer. PDCD4 blocks translation initiation complex by binding eIF4A via MA-3 domains or by directly binding 5′ mRNA internal ribosome entry sites with an RNA binding domain to suppress breast cancer progression and proliferation. Numerous regulators and biological processes including non-coding RNAs, proteasomes, estrogen, natural compounds and inflammation control PDCD4 expression in breast cancer. Loss of PDCD4 expression is also responsible for drug resistance in breast cancer. HER2 activation downregulates PDCD4 expression by activating MAPK, AKT, and miR-21 in aromatase inhibitor-resistant breast cancer cells. Moreover, modulating the microRNA/PDCD4 axis may be an effective strategy for overcoming chemoresistance in breast cancer. Down-regulation of PDCD4 is significantly associated with short overall survival of patients, which suggests that PDCD4 may be an independent prognostic marker for breast cancer.

Keywords: PDCD4, breast cancer, translational control, drug resistance, tumor suppressor

INTRODUCTION

Programmed cell death 4 (PDCD4) was first isolated as an antigen in proliferating cells that is bound by the monoclonal antibody Pr-28. Subsequently, the PDCD4 gene was identified in different species, including humans (1, 2), rats (3), and chicken (4). The human PDCD4 protein is comprised of 469 amino acids, and the protein sequence is a highly conserved from Drosophila to humans. The mouse and human PDCD4 proteins share approximately 92% identity in amino acid sequence. The human PDCD4 gene was mapped at chromosome 10q24 (5). PDCD4 has been demonstrated to be a protein translation inhibitor and a tumor suppressor, and consistently its expression frequently decreased in numerous types of malignancies including breast, colon, liver, lung, pancreatic, and skin cancers (6, 7). Loss of PDCD4 expression is associated with poor prognosis of patients with breast cancer (8, 9). In our review, we searched literatures in pubmed with the keywords PDCD4 and breast cancer in all fields. According to the contents of the target references, the article will focus on the function, regulation, and prognostic value of PDCD4 in breast cancer as well as its role in drug resistance.
PDCD4 FUNCTIONS

Inhibition of Protein Translation

Using yeast-two hybrid, PDCD4 was identified as a binding partner of translation initiation factor 4A (eIF4A) (10). The PDCD4-eIF4A interaction was further confirmed by mutation and crystallography (11–13). Crystallography of PDCD4-eIF4A showed that one molecule of PDCD4 interacts with two molecules of eIF4A through two MA-3 domains in PDCD4. The Glu210, Glu249, and Asp253 residues in the N-terminal segment of the MA-3 domain and the Glu373, Arg414, and Asp418 residues in the C-terminal segment form the ionic interaction with Arg110 and Arg161 of eIF4A (11, 12). Mutation of Glu249 to Lys, Asp253 to Ala, Asp414 to Lys and/or Asp418 to Ala in PDCD4 abolish its ability to bind eIF4A and result in loss of the ability to inhibit protein translation (13). This indicates that binding with eIF4A is required for the inhibition of translation by PDCD4. How does PDCD4-eIF4A binding inhibits protein translation? One possible mechanism is that PDCD4 inhibits protein translation through suppression of eIF4A’s helicase activity (10). eIF4A is an ATP-dependent RNA helicase. The function of eIF4A in protein translation initiation is to unwind the structured mRNA, allowing the translation initiation complex scan the mRNA from 5’ to 3’ end to locate the translation initiation codon (14). Therefore, inhibition of eIF4A activity by PDCD4 is expected to suppress protein translation, especially translation of mRNAs with complexly structured 5’ untranslated regions (5’UTRs). PDCD4 was initially demonstrated to preferentially suppress translation of a luciferase mRNA with a stem loop-structured 5’UTR with free energy of -44.8 kcal/mol (13). This scenario was further confirmed by identification of the stress-activated-protein kinase interacting protein 1 (Sin1) and ribosomal S6 kinase 1 (S6K1) as PDCD4 targets, whose mRNAs have 5’UTRs that form secondary structures with free energies of -145 and -82.30 kcal/mol, respectively (15, 16). In agreement with inhibition of eIF4A by PDCD4, cells treated with an eIF4A inhibitor, silvestrol, had reduced the Sin1 protein abundance (16). It seems that the mRNAs that have 5’UTRs with a free energy greater than -44.8 kcal/mol are susceptible to translation inhibition by PDCD4. However, this notion requires identification and analysis of additional PDCD4 targets. In addition to inhibiting eIF4A activity, PDCD4 may inhibit translation of anti-apoptotic proteins such as Bcl-xl and XIAP by directly binding with their mRNAs at internal ribosome entry sites to block the translation initiation complex formation (17, 18). The mechanisms of translation inhibition by PDCD4 are summarized in Figure 1.

Suppression of Tumorigenesis

PDCD4 was initially suggested to be a tumor suppressor in transformation-resistant JB6 cells because the downregulation of PDCD4 expression by antisense RNA resulted in a gain of transformation-susceptible phenotype (19). Conversely, overexpression of PDCD4 cDNA in the transformation-susceptible JB6 cells endowed resistance to tumor promoter-induced transformation (20). Mouse epidermal JB6 cells consist of three variants including transformation-susceptible, transformation-resistant, and transformed cells. Transformation-susceptible JB6 cells are sensitive to tumor promoter-induced transformation such as that induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment. By contrast, transformation-resistant JB6 cells are resistant to TPA-induced transformation. Later, several additional studies demonstrated that PDCD4 not only inhibits tumor promoter-induced transformation but also suppresses cancer cell proliferation, migration, invasion, and metastasis (for detail please see reviews (21, 22)). In breast cancer, PDCD4 has been shown to be a pro-apoptotic factor and inhibits cell growth (23, 24). Overexpression of PDCD4 reduces the rate of proliferation and promotes apoptosis in T-47D, MDA-MB-231, and MCF-7 breast cancer cells (25, 26). Conversely, down-regulation or repression of PDCD4...
decreases apoptosis (27, 28). In addition to suppressing proliferation and cell growth, several studies also demonstrated that PDCD4 attenuates tumor invasion and metastasis. Immunohistochemical studies showed that PDCD4 expression was only slightly decreased in in situ ductal carcinoma samples but was markedly decreased in invasive ductal carcinoma samples (29). In addition, reverse phase protein arrays, a new technique to study the functional proteome in non-microdissected breast tumors (30), showed that loss of PDCD4 expression was significantly associated with lymph node metastasis in HER2- and ER-positive invasive breast carcinomas (31). These findings suggest that loss of PDCD4 expression promotes breast cancer invasion. This notion is further supported by in vitro studies showing that knockdown of PDCD4 boosts invasion of T47D cells (32). Recently, PDCD4 overexpression was demonstrated to suppress cell cycle progression from the G1 phase to the G2 phase in triple negative breast cancer (TNBC) cell line (33). Although it is clear that PDCD4 suppresses tumorigenesis in breast cancer, the underlying mechanism is still not fully understood. For example, PDCD4 inhibits invasion in breast cancer cells by reduction of inhibitors of metalloproteinases-2 (TIMP-2) expression (34, 35). TIMP-2 inhibits matrix metalloproteinase (MMP) activity to prevent degradation of the extracellular matrix and thereby impedes tumor cell migration and invasion (36). However, it is unknown of how PDCD4 inhibits TIMP-2 expression.

Currently, pieces of evidence suggest that PDCD4 may inhibit tumorigenesis through two possible mechanisms. As mentioned above, PDCD4 binds with eIF4A and inhibits its helicase activity. During translation initiation, eIF4A is required for the unwinding or mRNAs that have 5′ UTRs with secondary structures. Usually, mRNAs with 5′ UTRs that have secondary structures encode for growth factors, growth promotion genes, and proto-oncogenes (37). Thus, inhibition of eIF4A by PDCD4 is expected to cause suppression of cell proliferation, migration, and/or invasion. For example, PDCD4 inhibits Sin1 translation to attenuate cell invasion in colorectal carcinoma (16). Sin1 is a critical component of mammalian target of rapamycin complex 2 (mTORC2) that regulates Akt activation. Inhibition of Sin1 translation by PDCD4 results in reduction of Snail expression to suppress invasion via inactivation of Akt. In addition to the eIF4A-dependent mechanism, PDCD4 may repress tumorigenesis through an eIF4A-independent mechanism. Liwak et al. reported that PDCD4 directly binds with the mRNA of X-linked inhibitor of apoptosis (XIAP) at an internal ribosome binding site and inhibits XIAP translation by preventing the translation initiation complex formation (18). In addition, PDCD4 was reported to bind to rapamycin-insensitive companion of mTOR (Rictor), another key component of mTORC2, to repress mTORC2 activity (38), and this may regulate cell survival, migration, and invasion by inhibiting Akt phosphorylation. However, the role of PDCD4-Rictor binding in the suppression of tumorigenesis and the underlying mechanism needs further investigation.

### THE REGULATORS OF PDCD4 IN BREAST CANCER

#### Non-Coding RNAs (microRNAs, IncRNAs and CircRNAs)

Non-coding RNAs (NcRNAs) include microRNAs (miRNAs), long non-coding RNAs (IncRNAs), and circular RNAs (CircRNAs). All of these have been reported to regulate the expression of PDCD4 and thereby control tumorigenesis in breast cancer.

miRNAs are small non-coding RNA molecules found in plants, animals and some viruses. They play critical roles in RNA silencing and post-transcriptional regulation of target genes. Among miRNAs, microRNA-21 (miR-21) was first identified to regulate PDCD4 expression (39). miR-21 is classified as an “oncomiR” and is commonly overexpressed in many types of solid cancers including breast cancer (40–42). Overexpression of miR-21 is implicated in various processes of tumorigenesis through the suppression of PDCD4 expression. These include the suppression of apoptosis (43, 44), promotion of cell proliferation and tumor growth (45, 46), and stimulation of invasion and metastasis (47, 48). Moreover, miR-21 significantly augmented PD-L1 expression and immune escape via PI3K/Akt pathway activation by targeting PDCD4 in breast cancer cells. According to this trait, Anti-PD-L1 antibody could enhance T cell immune responses and reduces resistance of breast cancer cells to radiotherapy in nude mice (49). Lu et al. found that the 3′-UTR of the PDCD4 mRNA contains a functional binding site for miR-21 (50). The PDCD4 mRNA level in MCF-7 cells did not change in the miR-21-transfected cells while the PDCD4 protein level decreased by approximately 50%, indicating that the reduction of PDCD4 protein is a result of post-transcriptional repression (50). Conversely, inhibition or down-regulation of miR-21 expression results in augmented PDCD4 expression (51). In addition to miR-21, miR-17-5p (52), miR-206 (53), miR-183-5p (54), miR-421 (28) and miR-424 (55) were reported to inhibit PDCD4 expression to influence the malignant behaviors of breast cancer cells (56).

IncRNAs are longer than 200 bp and comprise the most complex group of NcRNAs. IncRNAs contain miRNA binding sites and function as molecular sponges to effectively inhibit the expression of downstream genes targeted by miRNAs (57). A recent study showed that the expression of PDCD4-targeting IncRNA, PDCD4-AS1, is down-regulated during breast cancer progression, and its expression is positively correlated with PDCD4 level in breast cancer tissue (58, 59). Depletion of PDCD4-AS1 results in promotion of cell proliferation and migration in breast cancer cells. It is believed that PDCD4-AS1 stabilizes PDCD4 mRNA by forming an RNA duplex to attenuate the interaction between PDCD4 mRNA and RNA decay promoting factor HuR (60). Moreover, LncRNA GAS5 interacts with miR-21 via miRNA binding elements in breast cancer. Mediated by this sponge mechanism, GAS5 is involved in the upregulation of a number of mRNAs that encode tumor suppressor proteins such as PDCD4 (61). A similar mechanism that IncRNA SLC16A1-AS1 may serve as an internal sponge of...
miR-182 to augment PDCD4 has been reported recently. SLC16A1-AS1 is downregulated in TNBC and overexpression of SLC16A1-AS1 could suppress TNBC cell proliferation (33).

The circRNAs were initially identified from RNA viruses in 1976 and are connected at the 3' and 5' ends by exon or intron cyclization to form complete ring structures. CircRNAs have abundant binding sites for non-coding RNAs and thus act via absorption of non-coding RNAs like a sponge. CircRNAs affect the stability or the translation of target RNAs by competitively binding with miRNAs (62). For example, Hsa_circ_0053063 is a circRNA generated from several exons of hydroxacyl CoA dehydrogenase trifunctional multienzyme complex subunit alpha (HADHA), and it inhibits cell viability, proliferation, and progression of breast cancer through stabilization of PDCD4 by targeting miR-330-3p (63). Similarly, Circ-NOL10 could suppress breast cancer carcinogenesis by upregulating PDCD4 via a circ-NOL10/miR-149-5p/miR-330-3p/miR-452-5p/PDCD4 pathway (64).

Exosomes are extracellular bilayer vesicles with diameters ranging from 30 to 100 nm that transfer a wealth of nucleic acids and proteins among cells under physiological and pathological conditions (65). Breast cancer cell-derived exosomes play an important role in promoting breast cancer bone metastasis, which is associated with the formation of a pre-metastatic niche via transferal of miR-21 to osteoclasts and consequent down-regulation of PDCD4 expression (66).

Proteasomal Degradation
Proteasomes are part of a major mechanism by which cells regulate the concentration of particular proteins as well as degrade misfolded and unneeded proteins. Proteasomes are complexes of proteolytic activity and the accumulation of damaged and misfolded proteins, and this contributes to the pathogenesis in many diseases (67). Proteasomal degradation is another important mechanism that regulates PDCD4 expression. In response to mitogens such as TPA, PDCD4 is rapidly phosphorylated at Ser67 by the 70-kDa ribosomal protein 6 kinase (p70S6K). The Ser67 phosphorylated PDCD4 is recognized and bound by the ubiquitin E3 ligase β-transducin repeat-containing 1 (β-TRCP-1). The subsequent ubiquitination targets PDCD4 for proteasomal degradation and ultimately promotes tumor formation (68). Down-regulation of p70S6K by p70s6k shRNA increased PDCD4 expression in MDA-MB-231 cells (69). In addition to p70S6K, it was reported that the other p70S6K family member, p90 ribosomal S6 kinase (p90RSK), was able to phosphorylate PDCD4 at Ser76 and lead to PDCD4 degradation in several TNBC cell lines (70). Conversely, ubiquitin-specific protease 4 (USP4) can increase PDCD4 expression through deubiquitination and subsequent inhibition of its degradation in MCF-7 cells (71). A recent study showed that the 5-phase kinase-associated protein 2 (SKP2) promotes PDCD4 phosphorylation at Ser67 and subsequently its proteasomal degradation, resulting in the promotion of breast cancer cell proliferation (72). Interestingly, PDCD4 was also reported to inhibit IGF1R/IR inhibitor-induced phosphorylation of p70S6K (15, 73), which suggests a feedback loop regulation between PDCD4 and p70S6K.

Inflammation
Accumulating evidence has shown that inflammation can promote all stages of tumorigenesis, including DNA damage, limitless replication, apoptosis evasion, sustained angiogenesis, self-sufficiency in growth signaling, insensitivity to anti-growth signaling, and tissue invasion/metastasis. An inflammatory tumor microenvironment may attenuate PDCD4 protein expression. For example, exposure of MCF-7 cells to conditioned medium from TPA-induced differentiated monocytes attenuate PDCD4 protein level. This conditioned medium contained proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and IL-8, which stimulate PI3K–mTOR signaling pathway and thereby facilitate p70S6K-dependent proteasomal degradation of PDCD4 (74). In addition, activation of the Cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2)/Interleukin-8 (IL-8) inflammatory pathway suppresses PDCD4 expression and promotes the invasion in MCF-7 cells (35). It also reported that proinflammatory cytokine transforming growth factor-β (TGF-β) stimulates miR-21 expression and thereby suppresses PDCD4 expression in MDA-MB-468 cells (75).

Estrogen
Lifetime estrogen exposure is widely accepted as a major risk factor for breast cancer development (76). Several epidemiological surveys indicate that supplementation with exogenous estrogen or a high level of endogenous estrogen significantly increase the incidence of breast cancer (77). In vitro studies also showed that dimerized estrogen binds with estrogen receptor (ER) and promotes cell proliferation and invasion of breast tumor cells (78). Natural estrogens include estradiol (E2), estrone (E) and estrotriol (E3), among which estradiol is the most bioactive form involved in breast tumorigenesis (79). Anti-estrogens are a class of drugs that prevent estrogens like E2 from mediating their biological effects in vivo. They act by blocking ER or by suppressing estrogen production. ICI-182780, an artificial anti-estrogen drug also named fulvestrant, can increase PDCD4 protein expression in ER-positive T-47D cells (25, 80). Interestingly, E2 treatment increases PDCD4 expression in MCF-7 cells by down-regulation of miR-21 in an ER-dependent manner (81). Further research proved that overexpression of ERα may up-regulate miR-21 to suppress PDCD4 expression in breast cancer cells (82). This interesting phenomenon can be interpreted as follows: if ER density is not increased, breast cancer cells may overexpress PDCD4 in the face of high estrogen levels, and if ER density is increased rising sensitivity to estrogen may decrease PDCD4 expression and thereby promote metastasis.

Natural Compounds
Sinomenine (Sino) is diffusely applied to heal rheumatoid arthritis and neuralgia. Gao et al. found that Sino exposure remarkably enhanced PDCD4 expression by inhibiting miR-29 in MDA-MB-231 cells (83). In addition, Gleditsia sinensis extract has been historically used in Chinese medicine and is considered one of the fundamental therapeutic herbs. The anti-
breast cancer effect for Gleditsia sinensis probably results in upregulation of PDCD4 expression to promote cell apoptosis (84, 85). Curcumin is a constituent of the yellow powder extracted from the roots of Curcuma longa Linn. It is used to treat various diseases including hepatic disorders, anorexia, diabetic wounds, and rheumatism. Treatment with curcumin could down-regulates miR-21 expression and consistently up-regulates PDCD4 to promote apoptosis in breast cancer cell lines (86). Andrographolide is regarded as a “natural antibiotic” and is present in Andrographis paniculata (87), and it has shown to inhibit breast cancer growth and metastasis in vivo and to suppress cell proliferation, migration, and invasion in vitro. Mechanistically, andrographolide inhibited nuclear factor-kappa B (NF-kB) and elevates PDCD4 expression through suppression of miR-21-5p (88).

Other Mechanisms to Regulate PDCD4 Expression
Retinoic acid receptors (RARs), which belong to steroid/thyroid hormone receptor gene family, are ligand-dependent transcription factors. They have been shown to inhibit the growth of breast cancer cells in vitro and in vivo. Afonja et al. treated T-47D and MCF-7 breast cancer cells with Am580 (a selective RARα agonist) and all-trans retinoic acid (ATRA, another RAR agonist derived from vitamin A retinoids) and found that PDCD4 expression was increased two- to five-fold. However, the detailed mechanism by which RAR agonists regulate PDCD4 expression is still unclear (25).

Human epidermal growth factor receptor-2 (HER2) is an oncogene, and its downstream signaling pathway plays important roles in the development and progression of certain aggressive types of breast cancer. HER2 antagonists (such as trastuzumab, pertuzumab and lapatinib) induce PDCD4 protein expression in T-47D cells, which express HER2 (25). Transfection of HER2 expression plasmid into MDA-MB-435 cells reduced PDCD4 expression by about 45% and concomitantly enhanced invasion and metastasis (89). Signal transducer and activator of transcription 3 (STAT3) was found to bind its response elements in the HER2 promoter to upregulate HER2 transcription in metastatic HER2-positive breast cancer. Moreover, STAT3 co-opts HER2 function by recruiting HER2 as its coactivator at the binding sites in the miR-21 promoter to enhance its expression, resulting in depression of PDCD4 (90).

The neuregulins (NRGs) comprise the largest subfamily of EGF-like polypeptide growth factors and act by binding to the ErbB/HER receptor tyrosine kinases. Breast cancer cells treated with NRGs have reduced phosphorylation of PDCD4 at Ser67, which results in increased PDCD4 stabilization due to avoidance of proteasomal degradation (91).

The chemical compound AC1MMYR2 (2,4-diamino-1,3-diazinane-5-carbonitrile, also known as NSC211332) was identified as a specific small-molecule inhibitor of miR-21 that blocks the ability of Dicer to process pre-miR-21 to mature miR-21. AC1MMYR2 up-regulates the expression of PDCD4 to suppress proliferation and invasion in breast cancer (92).

In brief, various type of regulators control PDCD4 expression to influence hallmarks of breast cancer. Information on these regulatory factors is summarized in Table 1. Meanwhile, PDCD4 expression in different subtypes of breast cancer cell lines and tissues is summarized in Table 2.

PDCD4 AND DRUG RESISTANCE IN BREAST CANCER
Although various therapeutic agents such as tamoxifen, docetaxel, cisplatin, carboplatin, doxorubicin, gemcitabine, and mitoxantrone can improve overall survival and quality of life to some extent, patients eventually develop resistance to these treatments. The 5-year survival rate for patients with stage IV breast cancer is still as low as 20% (93). Thus, it is urgent to find new approaches that reduce drug resistance and improve the effectiveness of chemotherapy by understanding the relevant mechanisms of drug resistance in breast cancer. Increasing evidence suggests that up-regulation of PDCD4 in breast cancer may improve the sensitivity to systemic therapeutic drugs, especially for patients given neoadjuvant chemotherapy (preoperative chemotherapy where radical surgery is feasible), and thereby reduce tumor size, increase the chance of breast-conserving surgery and prolong lifespan.

PDCD4 and Resistance to Endocrine Therapy
Estrogens bind to ERs in the nucleus and promote their association with specific estrogen-response elements in the promoter region of target genes. This classic mechanism regulates the development of normal breast tissue and the progression of cancer cells (94). Based on the above mechanism, there are two main strategies to treat breast cancer with endocrine drugs (1): reduce the production of estrogen in the body; (2) competitively inhibit or destroy ERs. There are two main types of ERs in humans that have distinct functions: ERα and ERβ (95). ERα is expressed predominantly as a 66-kD transcript in breast cancer. ERβ has structural homology to ERα, particularly in their DNA-binding domains (95%) amino acid identity and in their ligand-binding domains (55% amino acid identity) (96). ERα is an important marker for breast cancer treatment as altered ERα signaling may cause resistance to endocrine therapy (97). By contrast, ERβ is proposed to inhibit ERα activity and may impair breast cancer cell proliferation by repressing the activation of the MAPK and PI3K signaling pathways (98, 99). ERβ agonists such as LY500307, ERB-041 and WAY200070 efficiently inhibit breast cancer cell growth and invasion. ERβ is now an interesting therapeutic target for patients with triple-negative breast cancer, who lack expression of ERα (100).

About 60%–70% of patients with breast cancer have ER-positive tumors (101). Therefore, inhibition of ER activity is the first therapeutic approach applied for patients with ER-positive breast cancer. Tamoxifen (TAM), a selective estrogen receptor modulator (SERM), is the most common drug for the
treatment of ER-positive cancers (102). Nevertheless, approximately 40% of initially ERα-positive breast tumors become resistant to tamoxifen and other endocrine treatments (103). There is a chance of ER antagonists may be due to: [1] overexpression of epidermal growth factor receptor (EGFR) and/or the oncogene HER2/neu/ErbB2 (104); [2] splice variants or point mutations in ER (105); [3] alterations in nuclear levels of ER coactivator or corepressor proteins, such as increased coactivator amplified in breast cancer 1 (AIB1) (106) or decreased corepressor nuclear receptor corepressor 1 (NCOR1) gene (107); [4] activation of the MAPK and PI3K/AKT signaling pathways (108, 109); and [5] increased expression of miR-221/222, which downregulate ER post-transcriptionally (110).

PDCD4 enhances sensitivity to various endocrine therapeutic drugs. Colburn and colleagues showed that down-regulation of PDCD4 by antisense RNA significantly reduced chemosensitivity to TAM in MCF-7 cells (111). In addition, PDCD4 is an independent predictive marker for resistance to TAM therapy in recurrent ER-positive breast cancer (112, 113). However, the mechanism through which PDCD4 enhances chemosensitivity to SERMs in breast cancer remains unclear.

### Table 1: Information of PDCD4 regulators in breast cancer.

| Name | Type | Regulatory Target or Pathways | Up/Down- Regulation | Ref No. |
|------|------|------------------------------|---------------------|---------|
| miR-21 | NcRNA | 3‘-UTR of PDCD4 | Down | 37, 47 |
| miR-17-5p | NcRNA | 3‘-UTR of PDCD4 | Down | 48 |
| miR-206 | NcRNA | 3‘-UTR of PDCD4 | Down | 49 |
| miR-183-5p | NcRNA | 3‘-UTR of PDCD4 | Down | 50 |
| miR-421 | NcRNA | 3‘-UTR of PDCD4 | Down | 51 |
| miR-424 | NcRNA | 3‘-UTR of PDCD4 | Down | 52 |
| PDCD4-AS1 | NcRNA | miRNA of PDCD4 | Up | 53 |
| LncRNA GAS5 | NcRNA | miR-21 | Up | 54 |
| SLC16A1-AS1 | NcRNA | miR-182 | Up | 55 |
| Hsa_circ_0053063 | NcRNA | miR-330-3p | Up | 56 |
| Circ-NOL10 | NcRNA | miR-149-5p/miR-330-3p/miR-452-5p | Up | 57 |
| p70S6K | Ribosomal protein | Ser89 phosphorylation | Down | 58, 59 |
| p90RSK/RSK | Ribosomal S6 kinase | S15 phosphorylation/MAPK pathway | Down | 60, 61 |
| USP4 | Ubiquitin-specific protease | Deubiquitination | Up | 62 |
| SKP2 | S-phase kinase | Ser98 phosphorylation/ AKT pathway | Down | 63, 64 |
| TNF-α/IL-6/IL-8 | Proinflammatory cytokines | PI3K/mTOR/p70S6K pathway | Down | 65, 66 |
| TOF-β | Proinflammatory cytokines | miR-21 | Down | 67 |
| Cox-2 | Cyclooxygenase | COX-2/PGE2/IL-8 inflammatory pathway | Down | 68 |
| Estradiol | Sexual Hormone | miR-21 | Up | 69 |
| Fulvestrant | Antiestrogen drug | Estrogen | Up | 70 |
| Snomine | Natural compounds | miR-29 | Up | 71 |
| Gleditsia sinensis | Natural compounds | miR-183 | Up | 72, 73 |
| Curcumin | Natural compounds | miR-21 | Up | 74 |
| Androgapholide | Natural compounds | NF-κB/miR-21-5p pathway | Up | 75 |
| Am580 | Selective RARα-agonist | Unclear | Up | 76 |
| ATRA | Selective RARα-agonist | Unclear | Up | 77 |
| FOXP3 | Tumor suppressor gene | Unclear | Up | 78 |
| Trastuzumab/Pertuzumab/ Lapatinib | HER-2/neu antagonist | Unclear | Up | 79 |
| Stat3 | Oncogene | Her-2/miR-21 | Down | 80 |
| Neuregulins | Growth factor | Reduce Ser89 phosphorylation | Up | 81 |
| Exosomes | Extracellular vesicle | miR-21–3‘-UTR of PDCD4 | Down | 82 |
| AC1MMYR2 | miRNA inhibitor | miR-21 | Up | 83 |

### Table 2: PDCD4 expression in different subtypes of breast cancer.

| Cell line/Tissue Name | Subtype | Technique | Up/Down-regulation | Ref No. |
|----------------------|---------|-----------|---------------------|---------|
| Pregnancy-associated breast cancer | N/A | RT-PCR/IHC | Downregulate | 7 |
| IDC | N/A | IHC | Upregulate in cytoplasm and Downregulate in nucleus | 8 |
| LET-R / LTEDaro | LuminalA | RT-PCR/IHC | Downregulate | 9 |
| HER2aro | Her2 (+) | RT-PCR/IHC | Downregulate | 9 |
| DOIS/IDC | N/A | IHC | Downregulate in IDC but slightly decreased in DOIS | 29 |
| ER+ breast cancer tissue | N/A | Reverse phase protein arrays | Downregulation was associated with node positivity | 30 |
| MDA-MB-231 | TNBC | RT-PCR/IHC | Downregulate | 31, 32 |
| HCC1937 | TNBC | RT-PCR | Downregulate | 33 |
| MDA-MB-468 | TNBC | RT-PCR | Downregulate | 34 |
| T47D | LuminalA | Western Blot | Downregulate | 35, 36 |
post-menopausal breast cancer and block the peripheral conversion of androgens into estrogens and thereby reduce estrogen levels. Aromatase is the rate-limited enzyme for estrogen biosynthesis. As breast and ovarian cancer cells require estrogen to grow, AIs are administered to either block the production of estrogen or block the action of estrogen on receptors. Unfortunately, resistance to AI treatment is a significant clinical problem for a considerable number of patients with ER-positive breast cancer (114). Chen and his colleagues found that PDCD4 expression was down-regulated in AI-resistant breast cancer cells, and this down-regulation significantly correlated with activation of HER2 signaling in ER-positive breast tumors. HER2 downregulates PDCD4 expression by activating MAPK, AKT, and miR-21 in AI-resistant breast cancer cells. Overexpression of PDCD4 re-sensitizes AI-resistant breast cancer cells to AI, which suggests the potential role of PDCD4 in AI-resistant breast cancer (9).

PDCD4 and Chemoresistance

PDCD4 is also associated with paclitaxel and doxorubicin resistance in breast cancer (115). Bourguignon et al. found that PDCD4 expression is down-regulated when MCF-7 breast cancer cells are treated with doxorubicin or paclitaxel (116). De Mattos et al. also reported that PDCD4 silencing by siRNAs enhances the resistance of SKBR3 breast cancer cells to paclitaxel and doxorubicin (117). In addition, it was suggested that the hyaluronan-CD44 interaction induced miR-21 production, and the consequent down-regulation of PDCD4 decreased apoptosis and increased the survival of MCF-7 cells and mediated resistance to both paclitaxel and doxorubicin treatment (116). Moreover, recent studies indicated that the miRNA/PDCD4 axis could modulate chemosensitivity in multiple resistant cancers (118–122). Taken together, this suggests that modulation of this axis may be an effective strategy for overcoming chemoresistance in breast cancer. Table 3 summarizes the relationship between PDCD4 and drug resistance by breast cancer as well as the possible related mechanisms.

| Drug Name        | Type          | Mechanism                                      | Ref No. |
|------------------|---------------|-----------------------------------------------|---------|
| Tamoxifen        | SERM          | Unclear                                       | 106-108 |
| Letrozole/Anastrozole/Exemestane | AI           | HER2 activate MAPK, AKT and miR-21 pathway    | 10      |
| Paclitaxel       | Phytochemical | Hyaluronan-CD44 interaction induced miR-21 expression | 110-112 |
| Doxorubicin      | Antibiotic    | Hyaluronan-CD44 interaction induced miR-21 expression | 110-112 |

DISCUSSION

PDCD4 is an important suppressor of breast cancer tumorigenesis. Loss of PDCD4 promotes tumor cells proliferation, migration and invasion, and is associated with lymph node metastasis and worse disease-free survival in patients with ER- and HER2-positive breast cancer. This implicates PDCD4 as a possible prognostic marker. Moreover, PDCD4 has been shown to increase the sensitivity of breast cancer cells to endocrine therapy and chemotherapy, which render it as a relevant therapeutic target to overcome chemoresistance. Thus, compounds that elevate PDCD4 expression are valuable agents for the combination of endocrine therapies or chemotherapies for breast cancer.

Taken together, the future research hotspot for the roles of PDCD4 in breast cancer will likely revolve around the following aspects: [1] the function PDCD4 as a biomarker for breast cancer diagnosis, prognosis, and drug-resistance; [2] the identification of novel upstream regulators and downstream target genes of PDCD4 and molecular biological mechanisms; [3] the development of small molecular and targeted drugs related to PDCD4.

AUTHOR CONTRIBUTIONS

JZ contributed to conception and design of the review. JZ and YCL organized the tables and the figure. QC wrote the first draft of the manuscript. HSY wrote one section (PDCD4 function) of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by grant from the National Natural Science Foundation of China (No. 81402192).

ACKNOWLEDGMENTS

We would like to thank Editage (www.editage.cn) for English language editing.
REFERENCES

1. Matsuhashi HY, Satsuki H, Tsugita A, Hori K. Isolation of a Novel Gene Form a Human Cell Line With Pr-28 MAb Which Recognizes a Nuclear Antigen Involved in the Cell Cycle. Res Commun Biochem (1997) 1:109–20.

2. Arzoni J, Zatepsina O, Abebe B, Bennett IR, Kanakaris P, Perussia B. Differential Transcriptional Regulation of CD161 and a Novel Gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T Cells. J Immunol (1998) 161:7349–500.

3. Goke A, Goke R, Knolle A, Trusheim H, Schmidt H, Wilmen A, et al. DUG is a Novel Homologue of Translation Initiation Factor 4G That Binds Eif4A. Biochem Biophys Res Commun (2002) 297(1):78–82. doi: j.pharmthera./s0006-2912(02)02129-0

4. Schlichter U, Kattmann D, Appl H, Miethe J, Brehmer-Fastnacht A, Schacht A, et al. The Complex of Liver Enzyme Is a Novel Eukaryotic Translation Initiation Factor 4A Binding Protein That Inhibits Translation. Mol Cell Biol (2003) 23(1):113–4. doi: 10.1186/1471-2407-9-163

5. Korakiti AM, Mouta A, Hachicha N, El-Bayoumi MS, Gaborieau V, et al. Expression of miR-21 and Its Targets (PTEN, PDCD4, TFF1) in Flat Epithelial Atypia of the Breast in Relation to Ductal Carcinoma in Situ and Invasive Carcinoma [Research Support, Non-U.S. Gov’t]. BMC Cancer (2009) 9:163. doi: 10.1186/1471-2407-9-163

6. Chen Z, Yuan YC, Wang Y, Liu Z, Chan HJ, Chen S. Down-Regulation of Programmed Cell Death 4 (PDCD4) is Associated With Aromatase Inhibitor Resistance and a Poor Prognosis in Estrogen Receptor-Positive Breast Cancer [Research Support, N.I.H., Extramural]. Breast Cancer Res Treat (2015) 152(1):29–39. doi: 10.1007/s10539-015-3446-8

7. Liwak U, Thakor N, Jordan LE, Roy R, Lewis SM, Pardo OE, et al. Tumor Suppressor PDCD4 Represses Internal Ribosome Entry-Site-Mediated Translation of Antipoptotic Proteins and is Regulated by S6 Kinase 2. Mol Cell Biol (2012) 32(10):1818–29. doi: 10.1128/MCB.06317-11

8. Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H, et al. Differentially Expressed Protein Pdc4 Inhibits Tumor Promoter-Induced Neoplastic Transformation [Research Support, U.S. Gov’t, P.H.S.]. Proc Natl Acad Sci U S A (1999) 96(24):14037–42. doi: 10.1073/pnas.96.24.14037

9. Yang HS, Knies JL, Stark C, Colburn NH. Pcd4 Suppresses Tumor Phenotype in Jb6 Cells by Inhibiting Ap-1 Transactivation. Oncogene (2003) 22(24):3712–20. doi: 10.1038/sj.onc.1206433

10. Matsuhashi S, Manirujjaman M, Hamajima H, Ozaki I. Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Functions. Int J Mol Sci (2019) 20(9):2304. doi: 10.3390/ijms20092304

11. Wang Q, Yang HS. The Role of Pdc4 in Tumour Suppression and Protein Translation. Biol Cell (2018). doi: 10.1111/boc.201800014

12. Loh PG, Yang HS, Walsh MA, Wang X, Wang YL, Wang C, et al. Aberrations in Translational Regulation are Associated With Poor Prognosis in Estrogen Receptor-Positive Breast Cancers. J Invest Breast Cancer (2020) 10(1):1773. doi: 10.3389/fonc.2020.01773

13. Rogers GW Jr., Komar AA, Merrick WC. Eif4a: The Godfather of the DEAD Box Helicases [Research Support, Non-U.S. Gov’t]. Mol Cell Biol.24.9.3894-3906.2004

14. Fan D, Zeng C, Wang S, Han J, Zhu L, Zhao H, et al. Forkhead Box P3 Promotes Breast Cancer Cell Apoptosis by Regulating Programmed Cell Death 4 Expression. Oncol letters (2020) 16(6):292. doi: 10.3892/ol.2020.12155

15. Afonja O, Juste D, Das S, Matsuhashi S, Samuels HH. Induction of Pdc4 as a Tumor Suppressor Gene Expression by RAR Agonists, Antitestrogen and HER-2/Neu Antagonist in Breast Cancer Cells Evidence for a Role in Apoptosis. Oncogene (2004) 23(49):8135–45. doi: 10.1038/sj.onc.1207983

16. Modelska A, Turo R, Russell R, Beaton J, Berratto T, Spriggs K, et al. The Malignant Phenotype in Breast Cancer Is Driven by Eif4a-Mediated Changes in the Translational Landscape. Cell death disease (2015) 6: e1603. doi: 10.1038/cddis.2014.542

17. Bitomsky N, Wethkamp N, Marikkannu R, Klempnauer KH. siRNA-Mediated Knockdown of Pdc4 Causes Upregulation of P21 (Waf1/Cip1) Expression [Research Support, Non-U.S. Gov’t]. Oncogene (2008) 27(35):4820–9. doi: 10.1038/onc.2008.115

18. Wang Y, Liu Z, Shen J. MicroRNA-421-Targeted PDCD4 Regulates Breast Cancer Cell Proliferation. Int J Mol Med (2019) 43(1):267–75. doi: 10.3892/imjmm.2018.3932

19. Wen YH, Shi X, Chiriboga L, Matsuhashi S, Yee H, Afonja O. Alterations in the Expression of PDCD4 in Ductal Carcinoma of the Breast [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Oncol Rep (2007) 18(6):1387–93.

20. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, et al. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-Microdissected Human Cancers. Clin Proteomics (2010) 6(4):129–51. doi: 10.1186/s12191-010-0955-y

21. Meric-Bernstam F, Chen H, Akcaakurah A, Do KA, Luuch A, Hennessy BT, et al. Aberrations in Translational Regulation are Associated With Poor Prognosis in Hormone Receptor-Positive Breast Cancer. Breast Cancer Res BCR. (2012) 14(5):R138. doi: 10.1186/bcr3343

22. Santhanam AN, Baker AR, Hegamyer G, Kirschmann DA, Colburn NH. Pdc4 Repression of Lysyl Oxidase Inhibits Hypoxia-Induced Breast Cancer Cell Invasion [Research Support, N.I.H., Extramural]. Oncogene (2010) 29(27):3921–32. doi: 10.1038/onc.2010.158

23. Jiang B, Liu Q, Gai J, Guan J, Li Q. LncRNA SLC16A1-AS1 Regulates the mir-182/PDCD4 Axis and Inhibits the Triple-Negative Breast Cancer Cell Cycle. Immunopharmacol Immunotoxicol (2022) 22:1–18. doi: 10.1080/08923973.2022.2056482

24. Gonzalez-Villasana V, Nieves-Alicea R, McMurtry V, Gutierrez-Puente Y, Tari AM. Programmed Cell Death 4 Inhibits Leptin-Induced Breast Cancer Cell Invasion [Research Support, Non-U.S. Gov’t]. Oncol Rep (2012) 27(3):861–6. doi: 10.3892/or.2011.1600

25. Nieves-Alicea R, Colburn NH, Simeone AM, Tari AM. Programmed Cell Death 4 Inhibits Breast Cancer Cell Invasion by Increasing Tissue Inhibitor of Metalloproteinases-2 Expression [Research Support, N.I.H., Extramural...
36. Strongin AV, Marmer BL, Grant GA, Goldberg GL. Plasma Membrane-Dependent Activation of the 72-kDa Type IV Collagenase is Complexed With TIMP-2. *J Biol Chem* (1993) 268(19):14033–9.

doi: 10.1074/jbc.268.19.14033-5

37. De Benedetti A, Harris EL. Life Expression in Tumors: Its Possible Role in Progression of Malignancies [Review]. *Int J Biochem Cell Biol* (1999) 31(1):39–72. doi: 10.1016/S1357-2725(98)00132-0

38. Bera A, Das F, Ghosh-Choudhury N, Kasinath BS, Abboud HE, Choudhury B. MicroRNA-21-Induced Dissociation of PDCD4 From Rictor Contributes to Akt-TRKbeta-Mtorc1 Axis to Regulate Renal Cancer Cell Invasion. *Exp Cell Res* (2014) 328(1):99–117. doi: 10.1016/j.yexcr.2014.06.022

39. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) Post-Transcriptionally Downregulates Tumor Suppressor Pdc4 and Stimulates Invasion, Intravasation and Metastasis in Colorectal Cancer. *Oncogene* (2008) 27(15):2128–36. doi: 10.1038/sj.onc.1210856

40. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA Gene Expression Deregulation in Human Breast Cancer. *Cancer Res* (2005) 65(16):7065–70. doi: 10.1158/0008-5472.CAN-05-1783

41. Diederichs S, Haber DA. Sequence Variations of microRNAs in Human Colorectal Cancer. *Oncogene* (2007) 26(19):2799–803. doi: 10.1038/sj.onc.1210083

42. Bera A, Choudhury B. MicroRNA-21 Expression in Breast Cancer Through Repressing Deltaef1 Promotes Protein Translation and Cell Growth. *Oncol Lett* (2018) 16(3):225–33. doi: 10.3892/ol.2016.7002

43. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, et al. MicroRNA-21 is an Antiapoptotic Factor in Human Glioblastoma Cells. *Clin Cancer Res* (2005) 11(1):79–89. doi: 10.1158/1078-0432.CCR-04-0157

44. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Lukina SS, et al. Long Noncoding RNA GAS5 in Breast Cancer: Epigenetic Mechanisms and Biological Functions. *J Int Mol Sci* (2021) 22(13):6810. doi: 10.3390/joms22136810

45. Zhong Y, Du Y, Yang X, Mo Y, Fan C, Xiong F, et al. Circular RNAs Function as ceRNAs to Regulate and Control Human Cancer Progression. *Mol Cancer* (2018) 17(1):79. doi: 10.1186/s12943-018-0827-8

46. Ji C, Hu J, Wang X, Zheng W, Deng X, Song H, et al. Natural Antisense IncRNA Controls Breast Cancer Progression by Promoting Tumor Suppressor Gene mRNA Stability. *PloS Genet* (2016) 12(11):e1007082. doi: 10.1371/journal.pgen.1007082

47. Filippova EA, Fridman MV, Burdennyy AM, Loginov VI, Bronova IV, Lukina SS, et al. Long Noncoding RNA GAS5 in Breast Cancer: Epigenetic Mechanisms and Biological Functions. *Int J Mol Sci* (2021) 22(13):6810. doi: 10.3390/joms22136810

48. Filippova EA, Fridman MV, Burdennyy AM, Loginov VI, Bronova IV, Lukina SS, et al. Long Noncoding RNA GAS5 in Breast Cancer: Epigenetic Mechanisms and Biological Functions. *Int J Mol Sci* (2021) 22(13):6810. doi: 10.3390/joms22136810

49. Liu Z, Liu M, Strubinski V, Klinge CM, Ramos KS, Colburn NH, et al. MicroRNA-21 Promotes Cell Transformation by Targeting the Programmed Cell Death 4 Gene. *Oncogene* (2008) 27(31):4373–9. doi: 10.1038/sj.onc.1208037

50. Yin H, Xiong G, Guo S, Xu C, Xu R, Guo P, et al. Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133. *Mol Ther* (2019) 27(7):2125–61. doi: 10.1016/j.ymthe.2019.04.018

51. Im YJ, Andrade J, Wickstrom E. Non-Specific Blocking of miR-17-5p Guide Strand in Triple Negative Breast Cancer Cells by Amplifying Passenger Strand Activity. *PLoS One* (2015) 10(12):e0142574. doi: 10.1371/journal.pone.0142574

52. Lin CC, Sharma SB, Farrugia MK, McLaughlin SL, Ice RJ, Loskutov YV, et al. Kruppel-Like Factor 4 Signals Through microRNA-206 to Promote Tumor Initiation and Cell Survival. *Oncogenesis* (2015) 4:e155. doi: 10.1038/oncsci.2015.8

53. Li Y, Jiang D, Zhang Q, Liu X, Cai Z, Ubiquitin-Specific Protease 4 Inhibits Breast Cancer Cell Growth Through the Upregulation of PDCD4. *Int J Mol Med* (2016) 38(3):803–11. doi: 10.3892/ijmm.2016.2685
64. Cai Y, Zhang C, Zhan L, Cheng L, Lu D, Wang X, et al. Anticancer Effects of Gleditsia Sinensis Extract in Rats Transplanted With Hepatocellular Carcinoma. J Endocrinol 2020. doi: 10.1530/JOE-20-00661
65. Mercogliano MF, et al. Stat3 Regulates ErbB-2 Expression and Co-opts DROSHA-Mediated microRNA Maturation. Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4415-20. doi: 10.1073/pnas.1012048108
66. Enmark E, Gustafsson JA. Oestrogen Receptors - an Overview. Mol Cell Endocrinol 2003;200(1-2):171-9. doi: 10.1016/S0303-7207(03)00339-2
67. Shi Z, Zhang J, Qian X, Han L, Zhang K, Chen L, et al. AC1MMYR2, an E2F1 Coactivator to Promote Breast Cancer Cell Proliferation and Epithelial-Mesenchymal Transition and Suppresses Tumor Growth and Progression. Cancer Res 2013;73(17):5519-31. doi: 10.1158/0008-5472.CAN-13-0280
68. Malhotra A, Jain M, Prakash H, Vasquez KM, Jain A. The Regulatory Roles of Long non-Coding RNAs in the Development of Chemoresistance in Breast Cancer. Oncotarget 2017;8(66):110671-84. doi: 10.18632/oncotarget.22577
69. Gruber Cj, Tschuguel W, Schneebeger C, Huber JC. Production and Actions of Estrogens. N Engl J Med 2002;346(5):340-52. doi: 10.1056/NEJMra000471
70. Hawkins MB, Thornton JW, Crews D, Skipper JK, Dotte A, Thomas P. Identification of a Third Distinct Estrogen Receptor and Reclassification of Estrogen Receptors in Teleosts. Proc Natl Acad Sci U S A. 2000;97(20):10751-6. doi: 10.1073/pnas.97.20.10751
71. Enmark E, Gustafsson JA. Oestrogen Receptors – an Overview. J Intern Med 2000;247(2):133-8. doi: 10.1046/j.1365-2786.1999.00545.x
72. Zhang T, Zhu J, Li Z, Loret J, Zhao C, Dahman-Wright K, et al. P21-Activated Kinase Group II Small Compound Inhibitor GNE-2861 Perturbs Estrogen Receptor Alpha Signaling and Restores Tamoxifen-Sensitivity in Breast Cancer Cells. Oncotarget 2015;6(41):43853-68. doi: 10.18632/oncotarget.6081
73. Chang EC, Frasor J, Komb B, Katzenellenbon BS. Impact of Estrogen Receptor Beta on Gene Networks Regulated by Estrogen Receptor Alpha in Breast Cancer Cells. Endocrinology 2006;147(10):4831-42. doi: 10.1210/en.2006-0563
74. Cotrim CZ, Fabris V, Doria ML, Lindberg K, Gustafsson JA, Amado F, et al. Estrogen Receptor Beta Growth-Inhibitory Effects are Repressed Through Activation of MAPK and PI3K Signalling in Mammary Epithelial and Breast Cancer Cells. Oncogene 2013;32(19):2390-402. doi: 10.1038/onc.2012.261
75. Bianchini G, Balco JM, Mayer IA, Sanders ME, Gianni L. Triple-Negative Breast Cancer: Challenges and Opportunities of a Heterogeneous Disease. Nat Rev Clin Oncol 2016;13(11):674-90. doi: 10.1038/nrclinonc.2016.66
76. Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant Endocrine Therapy for 46–66. Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 2014;32(21):2255-69. doi: 10.1200/JCO.2013.54.2258
77. Ring A, Dowsett M. Mechanisms of Tamoxifen Resistance. Endocrine-related cancer (2004) 11(4):643-58. doi: 10.1677/erc.0.0080191
78. Weihiu S, Saji S, Makinen S, Cheng G, Jensen EV, Warner M, et al. Estrogen Receptor (ER) Beta, a Modulator of ERalpha in the Uterus. Proc Natl Acad Sci U S A (2000) 97(11):5936-41. doi: 10.1073/pnas.97.11.5936
79. Dowsett M. Overexpression of HER-2 as a Resistance Mechanism to Hormonal Therapy for Breast Cancer. Endocrine-related cancer (2001) 8 (3):191-5. doi: 10.1677/erc.00081901
80. Herynk MH, Fuqua SA. Estrogen Receptor Mutations in Human Disease. Endocr Rev (2005) 26(5):869-98. doi: 10.1202/er.2003-000100
81. Louie MC, Zou JX, Rabinovich A, Chen HW. ACTR/AIB1 Functions as an E2F1 Coactivator to Promote Breast Cancer Cell Proliferation and Antiestrogen Resistance. Mol Cell Biol (2004) 24(12):5157-71. doi: 10.1128/MCB.24.12.5157-5171.2004
82. Girault I, Lerebours F, Amirar S, Tozlu S, Tubiana-Hulin M, Lidereau R, et al. Expression Analysis of Estrogen Receptor Alpha Coregulators in Breast Cancer: Evidence That NCOA1 Expression is Predictive of the Response to Tamoxifen. Clin Cancer Res (2003) 9(4):1239-66
83. Fan P, Yue W, Wang JP, Aijar S, Li Y, Kim TH, et al. Mechanisms of Resistance to Structurally Diverse Antiestrogens Differ Under Premenopausal and Postmenopausal Conditions: Evidence From In Vivo
Breast Cancer Cell Models. Endocrinology (2009) 150(5):2036–45. doi: 10.1210/en.2008-1195

109. Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, et al. Genome-Wide Analysis of Aromatase Inhibitor-Resistant, Tamoxifen-Resistant, and Long-Term Estrogen-Deprieved Cells Reveals a Role for Estrogen Receptor. Cancer Res (2008) 68(12):4910–8. doi: 10.1158/0008-5472.CAN-08-0303

110. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, et al. Targeted MS Assay Predicting Tamoxifen Resistance in Breast Cancer Tissues and Sera. Mol Oncol (2016) 10(1):24–39. doi: 10.1016/j.molonc.2015.07.004

111. Jansen AP, Camalier CE, Stark C, Colburn NH. Characterization of Programmed Cell Death 4 in Multiple Human Cancers Reveals a Novel Enhancer of Drug Sensitivity. Mol Cancer Ther (2004) 3(2):103–10.

112. De Marchi T, Liu NQ, Stingl C, Timmermans MA, Simid M, Look MP, et al. 4-Protein Signature Predicting Tamoxifen Treatment Outcome in Recurrent Breast Cancer. Mol Oncol (2016) 10(1):24–39. doi: 10.1016/j.molonc.2015.07.004

113. De Marchi T, Kuhn E, Dekker LJ, Stingl C, Brokman RB, Opdam M, et al. Targeted MS assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera. J Proteome Res (2016) 15(4):1230–42. doi: 10.1021/acs.jproteome.5b01119

114. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JPA. Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Breast Cancer: A Meta-Analysis. J Natl Cancer Inst (2006) 98(18):1285–91. doi: 10.1093/jnci/dji357

115. Tao L, Wu YQ, Zhang SP. MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting P27Kip1. J Biol Chem (2008) 283(44):29897–903. doi: 10.1074/jbc.M804612200

116. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, et al. Targeted MS Assay Predicting Tamoxifen Resistance in Breast Cancer Tissues and Sera. Mol Oncol (2016) 10(1):24–39. doi: 10.1016/j.molonc.2015.07.004

117. Jansen AP, Camalier CE, Stark C, Colburn NH. Characterization of Programmed Cell Death 4 in Multiple Human Cancers Reveals a Novel Enhancer of Drug Sensitivity. Mol Cancer Ther (2004) 3(2):103–10.

118. De Marchi T, Liu NQ, Stingl C, Timmermans MA, Simid M, Look MP, et al. 4-Protein Signature Predicting Tamoxifen Treatment Outcome in Recurrent Breast Cancer. Mol Oncol (2016) 10(1):24–39. doi: 10.1016/j.molonc.2015.07.004

119. Lei Y, Hu X, Li B, Peng M, Tong S, Xu Z, et al. miR-150 Modulates Cisplatin Chemosensitivity and Invasiveness of Muscle-Invasive Bladder Cancer Cells via Targeting PDCD4. In Vitro. Med Sci monitor Int Med J Exp Clin Res (2014) 20:1850–7. doi: 10.2659/M5.M81340

120. Ning FL, Wang F, Li ML, Yu ZS, Hao YZ, Chen SS. MicroRNA-182 Modulates Chemosensitivity of Human non-Small Cell Lung Cancer to Cisplatin by Targeting PDCD4. Diagn pathol (2014) 9:143. doi: 10.1186/1746-1596-9-143

121. Wang YQ, Guo RD, Guo RM, Sheng W, Yin LR. MicroRNA-182 Promotes Cell Growth, Invasion and Chemoresistance by Targeting Programmed Cell Death 4 (PDCD4) in Human Ovarian Carcinomas. J Cell Biochem (2013) 114 (7):1464–73. doi: 10.1002/jcb.24488

122. Zhao J, Cao J, Zhou L, Du Y, Zhang X, Yang R, et al. MiR-1260b Inhibitor Enhances the Chemosensitivity of Colorectal Cancer Cells to Fluorouracil by Targeting PDCD4/IGF1. Oncol letters (2018) 16(4):5131–9. doi: 10.3892/ol.2018.9307

123. Li JZ, Gao W, Ho WK, Lei WB, Wei WI, Chan JY, et al. The Clinical Association of Programmed Cell Death Protein 4 (PDCD4) With Solid Tumors and its Prognostic Significance: A Meta-Analysis. Chin J Cancer. (2016) 35(1):95. doi: 10.12659/MSM.891340

124. Madera S, Chervo MF, Chiauzzi VA, Pereyra MG, Venturutti L, Izzo F, et al. Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers With Good Prognosis. Horm Cancer. (2020) 11(5-6):218–39. doi: 10.1007/s12672-020-00392-4

Conflict of Interest: The authors declare that they conducted the work in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Cai, Yang, Li and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.